Bio Plus Co

Bio Plus Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Bio Plus Co (099430.KQ) as of Oct 21, 2026 is 343.17 %. In the previous year, Operating Cash Flow to Debt Ratio was 469.07 % — a change of -26.84% (lower).

OCF/Debt

343.17 %

YoY

-26.84%

Last updated:

Operating Cash Flow to Debt Ratio of Bio Plus Co is 2025 343.17 % . Operating Cash Flow to Debt Ratio of Bio Plus Co was 2024 469.07 % . It decreases by -26.84% lower compared to the previous year.

The Bio Plus Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
70.18 KRW
Jan 1, 2019
10,830.28 KRW
Jan 1, 2020
26,394.71 KRW
Jan 1, 2021
3,615.99 KRW
Jan 1, 2022
215.32 KRW
Jan 1, 2023
182.98 KRW
Jan 1, 2024
469.07 KRW
Jan 1, 2025
343.17 KRW
The Bio Plus Co OCF/Debt history
YEAROCF/DebtYoY
343.17 %-26.84%
469.07 %+156.35%
182.98 %-15.02%
215.32 %-94.05%
3,615.99 %-86.30%
26,394.71 %+143.71%
10,830.28 %+15,332.32%
70.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Operating Cash Flow to Debt Ratio of Bio Plus Co is 343.17 % in 2025.

Operating Cash Flow to Debt Ratio of Bio Plus Co changed from 469.07 % to 343.17 %, representing a -26.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Plus Co

All Key Metrics — Bio Plus Co